ToxStrategies, Inc., Asheville, North Carolina 28801, USA.
ToxStrategies, Inc., Katy, Texas 77494, USA.
Toxicol Sci. 2021 Feb 26;180(1):38-50. doi: 10.1093/toxsci/kfaa187.
Oral exposure to hexavalent chromium (Cr[VI]) induces intestinal tumors in mice. Mutagenic and nonmutagenic modes of action (MOAs) have been accepted by different regulatory bodies globally, the latter involving cytotoxicity-induced regenerative cell proliferation. However, concerns persist that all possible MOAs have not been fully considered. To address the potential for alternative MOAs, mechanistic data not represented in the existing two MOAs were evaluated. Relevant data were identified and organized by key characteristics of carcinogens (KCCs); literature related to epigenetics, immunosuppression, receptor-mediated effects, and immortalization were reviewed to identify potential key events associated with an alternative MOA. Over 200 references were screened for these four KCCs and further prioritized based on relevance to the research objective (ie, in vivo, oral exposure, gastrointestinal tissue). Minimal data were available specific to the intestine for these KCCs, and there was no evidence of any underlying mechanisms or key events that are not already represented in the two proposed MOAs. For example, while epigenetic dysregulation of DNA repair genes has been demonstrated, epigenetic effects were not measured in intestinal tissue, and it has been shown that Cr(VI) does not cause DNA damage in intestinal tissue. High-throughput screening data related to the KCCs were also evaluated, with activity generally limited to the two recognized MOAs. Collectively, no plausible alternative MOAs (or key events) were identified in addition to those previously proposed for Cr(VI) small intestine tumors.
经口接触六价铬(Cr[VI])会在小鼠中诱导肠道肿瘤。全球不同监管机构已经接受了致突变和非致突变作用机制(MOA),后者涉及细胞毒性诱导的再生细胞增殖。然而,人们仍然担心并非所有可能的 MOA 都已得到充分考虑。为了解决其他 MOA 的可能性,评估了现有两种 MOA 中未包含的机制数据。通过致癌物质的关键特征(KCCs)对相关数据进行了识别和组织;对与表观遗传学、免疫抑制、受体介导的作用和永生化相关的文献进行了综述,以确定与替代 MOA 相关的潜在关键事件。对这四个 KCCs 筛选了 200 多篇参考文献,并根据与研究目标的相关性(即体内、口服暴露、胃肠道组织)进行了进一步的优先级排序。对于这些 KCCs,针对肠道的具体数据很少,而且没有证据表明存在任何已经在两种提出的 MOA 中没有体现的潜在机制或关键事件。例如,虽然已经证明了 DNA 修复基因的表观遗传失调,但在肠道组织中没有测量到表观遗传效应,并且已经表明 Cr(VI)不会在肠道组织中造成 DNA 损伤。还评估了与 KCCs 相关的高通量筛选数据,其活性通常限于两种公认的 MOA。总的来说,除了先前提出的 Cr(VI)小肠肿瘤的 MOA 之外,没有发现其他合理的替代 MOA(或关键事件)。